BR0015056A - Composto, uso de um composto, composição farmacêutica, método de tratamento de infecções por hiv e kit farmacêutico - Google Patents
Composto, uso de um composto, composição farmacêutica, método de tratamento de infecções por hiv e kit farmacêuticoInfo
- Publication number
- BR0015056A BR0015056A BR0015056-8A BR0015056A BR0015056A BR 0015056 A BR0015056 A BR 0015056A BR 0015056 A BR0015056 A BR 0015056A BR 0015056 A BR0015056 A BR 0015056A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical
- pharmaceutical composition
- hiv infections
- treating hiv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
"COMPOSTO, USO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO DE TRATAMENTO DE INFECçõES POR HIV E KIT FARMACêUTICO". A presente invenção se refere a compostos tricíclicos da fórmula (I) ou suas formas estereoisoméricas, misturas estereoisoméricas ou suas formas de sais farmaceuticamente aceitáveis, que são úteis como inibidores de transcriptase reversa de HIV, composições farmacêuticas e kits de diagnóstico que compreendem as mesmas e métodos de uso para o tratamento de infecção viral ou como um reagente ou padrão de teste.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16032999P | 1999-10-19 | 1999-10-19 | |
US22617100P | 2000-08-17 | 2000-08-17 | |
PCT/US2000/028824 WO2001029037A2 (en) | 1999-10-19 | 2000-10-19 | Condensed naphthyridines as hiv reverse transcriptase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0015056A true BR0015056A (pt) | 2003-06-10 |
Family
ID=26856799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0015056-8A BR0015056A (pt) | 1999-10-19 | 2000-10-19 | Composto, uso de um composto, composição farmacêutica, método de tratamento de infecções por hiv e kit farmacêutico |
Country Status (19)
Country | Link |
---|---|
US (2) | US6593337B1 (pt) |
EP (1) | EP1222186A2 (pt) |
JP (1) | JP2003512375A (pt) |
KR (1) | KR20020079729A (pt) |
CN (1) | CN1409711A (pt) |
AU (1) | AU773309B2 (pt) |
BR (1) | BR0015056A (pt) |
CA (1) | CA2387896A1 (pt) |
CZ (1) | CZ20021353A3 (pt) |
EA (1) | EA200200471A1 (pt) |
EE (1) | EE200200202A (pt) |
HK (1) | HK1049150A1 (pt) |
HU (1) | HUP0300190A2 (pt) |
IL (1) | IL149219A0 (pt) |
MX (1) | MXPA02003958A (pt) |
NO (1) | NO20021835L (pt) |
PL (1) | PL355727A1 (pt) |
SK (1) | SK5342002A3 (pt) |
WO (1) | WO2001029037A2 (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596729B2 (en) | 2000-07-20 | 2003-07-22 | Bristol-Myers Squibb Company | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors |
ZA200300255B (en) | 2000-07-20 | 2004-09-28 | Bristol Myers Squibb Pharma Co | Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors. |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
EP1379248A1 (en) * | 2001-04-19 | 2004-01-14 | Bristol-Myers Squibb Company | Tricyclic compounds useful as hiv reverse transcriptase inhibitors |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
TW200306192A (en) | 2002-01-18 | 2003-11-16 | Bristol Myers Squibb Co | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7226461B2 (en) | 2002-04-19 | 2007-06-05 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US6909001B2 (en) | 2002-12-12 | 2005-06-21 | Pharmacia Corporation | Method of making tricyclic aminocyanopyridine compounds |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
EP1671096A4 (en) | 2003-09-29 | 2009-09-16 | Pelikan Technologies Inc | METHOD AND APPARATUS FOR PROVIDING IMPROVED SAMPLE CAPTURING DEVICE |
WO2005037095A1 (en) | 2003-10-14 | 2005-04-28 | Pelikan Technologies, Inc. | Method and apparatus for a variable user interface |
EP1706026B1 (en) | 2003-12-31 | 2017-03-01 | Sanofi-Aventis Deutschland GmbH | Method and apparatus for improving fluidic flow and sample capture |
US8828203B2 (en) | 2004-05-20 | 2014-09-09 | Sanofi-Aventis Deutschland Gmbh | Printable hydrogels for biosensors |
WO2005120365A1 (en) | 2004-06-03 | 2005-12-22 | Pelikan Technologies, Inc. | Method and apparatus for a fluid sampling device |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US7504969B2 (en) * | 2006-07-11 | 2009-03-17 | Data Domain, Inc. | Locality-based stream segmentation for data deduplication |
EP2265324B1 (en) | 2008-04-11 | 2015-01-28 | Sanofi-Aventis Deutschland GmbH | Integrated analyte measurement system |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
CN102388051A (zh) * | 2009-04-09 | 2012-03-21 | 贝林格尔.英格海姆国际有限公司 | Hiv复制抑制剂 |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US20140050778A1 (en) * | 2010-12-28 | 2014-02-20 | University Of Rochester | Nucleic acid binding compounds, methods of making, and use thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0065392B1 (en) | 1981-05-13 | 1985-02-13 | Imperial Chemical Industries Plc | Pharmaceutical compositions containing spiro succinimide derivatives |
DD204480A1 (de) | 1982-04-13 | 1983-11-30 | Meisel | Verfahren zur herstellung von in 10-stellung basisch substituierten 5,5-dimethyl-5,10-dihydro-benzo(b)(1,8)naphthyridinen |
ATE161535T1 (de) | 1989-04-20 | 1998-01-15 | Boehringer Ingelheim Pharma | 6,11-dihydro-5h-pyrido(2,3-b)(1,5)benzodiazepin 5-one und thione und ihre verwendung für die vorbeugung oder behandlung von aids |
ATE116320T1 (de) | 1989-04-20 | 1995-01-15 | Boehringer Ingelheim Pharma | 5,11-dihydro-6h-pyrido(2,3-b)(1,4)benzodiazepin 6-one und -thione und deren verwendung bei der vorbeugung und und behandlung von aids. |
US5171745A (en) | 1990-07-13 | 1992-12-15 | Du Pont Merck Pharmaceutical Company | Method of treating neurological dysfunction using neutrotransmitter enhancers |
US5087625A (en) | 1990-10-19 | 1992-02-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyridodiazepines and their use in the prevention or treatment of HIV infection |
AU2436792A (en) | 1991-08-16 | 1993-03-16 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
IL102764A0 (en) | 1991-08-16 | 1993-01-31 | Merck & Co Inc | Quinazoline derivatives,and pharmaceutical compositions containing them |
US5527819A (en) * | 1991-09-06 | 1996-06-18 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
WO1993020080A1 (en) | 1992-03-27 | 1993-10-14 | Schering Corporation | Bridged bis-aryl carbinol derivatives, compositions and methods of use |
US5665720A (en) | 1992-08-07 | 1997-09-09 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
EP0662078B1 (en) | 1992-09-28 | 2003-05-02 | Research Corporation Technologies, Inc. | Reagents for peptide couplings |
US5594001A (en) | 1993-04-08 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders |
DE4320347A1 (de) | 1993-06-19 | 1994-12-22 | Boehringer Mannheim Gmbh | Quinazolin-Derivate und diese enthaltende Arzneimittel |
WO1995012583A1 (en) | 1993-11-05 | 1995-05-11 | Merck & Co., Inc. | New quinazolines as inhibitors of hiv reverse transcriptase |
DE4344452A1 (de) | 1993-12-24 | 1995-06-29 | Hoechst Ag | Aza-4-iminochinoline, Verfahren zu ihrer Herstellung und ihre Verwendung |
US5750528A (en) | 1995-02-01 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease |
AU5270796A (en) | 1995-04-07 | 1996-10-23 | Novo Nordisk A/S | N-substituted azaheterocyclic carboxylic acids and esters th ereof |
US5874430A (en) | 1996-10-02 | 1999-02-23 | Dupont Pharmaceuticals Company | 4,4-disubstitued-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same |
US6124302A (en) | 1997-04-09 | 2000-09-26 | Dupont Pharmaceuticals | 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors |
-
2000
- 2000-10-18 US US09/691,249 patent/US6593337B1/en not_active Expired - Lifetime
- 2000-10-19 EP EP00973644A patent/EP1222186A2/en not_active Withdrawn
- 2000-10-19 BR BR0015056-8A patent/BR0015056A/pt not_active IP Right Cessation
- 2000-10-19 JP JP2001531836A patent/JP2003512375A/ja active Pending
- 2000-10-19 WO PCT/US2000/028824 patent/WO2001029037A2/en not_active Application Discontinuation
- 2000-10-19 IL IL14921900A patent/IL149219A0/xx unknown
- 2000-10-19 AU AU12137/01A patent/AU773309B2/en not_active Ceased
- 2000-10-19 CA CA002387896A patent/CA2387896A1/en not_active Abandoned
- 2000-10-19 CZ CZ20021353A patent/CZ20021353A3/cs unknown
- 2000-10-19 KR KR1020027005054A patent/KR20020079729A/ko not_active Application Discontinuation
- 2000-10-19 EA EA200200471A patent/EA200200471A1/ru unknown
- 2000-10-19 CN CN00817018A patent/CN1409711A/zh active Pending
- 2000-10-19 EE EEP200200202A patent/EE200200202A/xx unknown
- 2000-10-19 HU HU0300190A patent/HUP0300190A2/hu unknown
- 2000-10-19 SK SK534-2002A patent/SK5342002A3/sk unknown
- 2000-10-19 PL PL00355727A patent/PL355727A1/xx not_active Application Discontinuation
- 2000-10-19 MX MXPA02003958A patent/MXPA02003958A/es unknown
-
2002
- 2002-04-18 NO NO20021835A patent/NO20021835L/no not_active Application Discontinuation
- 2002-11-07 HK HK02108077.7A patent/HK1049150A1/zh unknown
-
2003
- 2003-04-24 US US10/422,202 patent/US20040002498A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20021835D0 (no) | 2002-04-18 |
WO2001029037A3 (en) | 2002-01-24 |
EP1222186A2 (en) | 2002-07-17 |
EE200200202A (et) | 2003-06-16 |
CZ20021353A3 (cs) | 2002-09-11 |
KR20020079729A (ko) | 2002-10-19 |
IL149219A0 (en) | 2002-11-10 |
MXPA02003958A (es) | 2002-12-10 |
CN1409711A (zh) | 2003-04-09 |
PL355727A1 (en) | 2004-05-17 |
AU1213701A (en) | 2001-04-30 |
NO20021835L (no) | 2002-06-18 |
AU773309B2 (en) | 2004-05-20 |
HK1049150A1 (zh) | 2003-05-02 |
US20040002498A1 (en) | 2004-01-01 |
CA2387896A1 (en) | 2001-04-26 |
US6593337B1 (en) | 2003-07-15 |
HUP0300190A2 (en) | 2003-05-28 |
JP2003512375A (ja) | 2003-04-02 |
EA200200471A1 (ru) | 2003-04-24 |
SK5342002A3 (en) | 2003-04-01 |
WO2001029037A2 (en) | 2001-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0015056A (pt) | Composto, uso de um composto, composição farmacêutica, método de tratamento de infecções por hiv e kit farmacêutico | |
BR9808513A (pt) | Composto, composição farmacêutica, método para tratamento de infecções por hiv e kit farmacêutico. | |
BRPI0413469A (pt) | derivados de piperazina para o tratamento de infecções por hiv | |
BR9917080A (pt) | Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica | |
BRPI0208811B8 (pt) | derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos | |
BRPI0212726B8 (pt) | compostos contendo lactamas, e derivados dos mesmos, composição farmacêutica que os compreende e seus usos | |
BR0312560A (pt) | Novas espiropiperidinas ou espiropirrolidinas tricìclicas | |
BR0013771A (pt) | Composto, métodos de tratamento de uma infecção viral em um mamìfero, de inibir a transcriptase reversa do hiv, e de prevenção da infecção do hiv ou de tratar a infecção do hiv, uso de um composto, e, composição farmacêutica | |
BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
BRPI0412659A (pt) | isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto | |
BRPI0408767B8 (pt) | inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica | |
BRPI0315958B8 (pt) | composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
BR0306927A (pt) | Compostos tricìclicos de 2-pirimidona úteis como inibidores de transcriptase reversa de hiv | |
BR0208987A (pt) | Composto tricìclicos úteis como inibidores de transcriptase reserva de hiv | |
TW200710091A (en) | (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors | |
BR0214649A (pt) | Derivados de aminotetralina como antagonistas do receptor muscarìnico | |
NO20065582L (no) | (1,lOB-dihydro-2-(amtnokarbonyl-fenyl)-SH-pyrazolo[1,5-C][1,3]benzoksazin-5-yl)fenylmetanonderivater som HIV-virusreplikasjonsinhibitorer | |
WO2004002410A3 (en) | 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors | |
MXPA03000434A (es) | Compuestos de 2-piridona triciclicos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana (vih). | |
BR9814933A (pt) | Composto, composicao farmaceutica e metodo de tratamento de infeccao por hiv. | |
ATE532509T1 (de) | Mittel zur hemmung des eintritts des hiv-virus | |
BR0007854A (pt) | Compostos sulfonamidas bis-aminoácidos inibidores de protease de hiv, composição farmacêutica e método de tratamento de infecções por hiv | |
BR0314709A (pt) | Derivados de pirazol | |
BR9712910A (pt) | ra o tratamento de infecção por hiv | |
BR9712755A (pt) | Composto, composição farmacêutica, método para o tratamento de infecção por hiv e kit farmacêutico útil para o tratamento de infecção por hiv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A, E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1929 DE 26/12/2007. |